• No results found

[PDF] Top 20 Targeting DNA Repair in Cancer: Beyond PARP Inhibitors.

Has 10000 "Targeting DNA Repair in Cancer: Beyond PARP Inhibitors." found on our website. Below are the top 20 most common "Targeting DNA Repair in Cancer: Beyond PARP Inhibitors.".

Targeting DNA Repair in Cancer: Beyond PARP Inhibitors.

Targeting DNA Repair in Cancer: Beyond PARP Inhibitors.

... ADP-ribosylation inhibitors are already in clinical development/use, given the essential role of ubiquitylation and de- ubiquitylation in the DDR, modulating DNA repair through the use of specific ... See full document

66

Synthetic lethal therapies for cancer: what's next after PARP inhibitors?

Synthetic lethal therapies for cancer: what's next after PARP inhibitors?

... of PARP inhibitors (PARPi) for the treatment of cancers in individuals with germline mutations in either BRCA1 or ...ovarian cancer and one for BRCA-mutated breast cancer; these agents have ... See full document

32

Emergence of rationally designed therapeutic strategies for breast cancer targeting DNA repair mechanisms

Emergence of rationally designed therapeutic strategies for breast cancer targeting DNA repair mechanisms

... of DNA repair and the discovery that tumors are frequently repair-defi cient provide a therapeutic oppor- tunity to selectively target this weakness, especially in breast ...breast cancer, the ... See full document

11

An update on PARP inhibitors for the treatment of cancer

An update on PARP inhibitors for the treatment of cancer

... (PARP) inhibitors (PARPi) has progressed greatly over the last few years and has shown encouraging results in the BRCA1/2 mutation–related ...molecular inhibitors; future and ongoing trials will ... See full document

10

Advances in using PARP inhibitors to treat cancer

Advances in using PARP inhibitors to treat cancer

... The Cancer Genome Atlas Research Project recently reported on the molecular aberrations in high grade ser- ous ovarian adenocarcinoma, demonstrating a defect in the HR pathway in half of the 489 tumors analyzed ... See full document

5

<p>PARP Inhibitors in Endometrial Cancer: Current Status and Perspectives</p>

<p>PARP Inhibitors in Endometrial Cancer: Current Status and Perspectives</p>

... endometrial cancer (EC) has a dismal prog- nosis due to poor response rates to conventional ...of cancer genetics and molecular biology has led to the devel- opment of targeted therapies, such as poly ... See full document

13

PARP inhibitors in the management of breast cancer: current data and future prospects

PARP inhibitors in the management of breast cancer: current data and future prospects

... novel cancer therapies include agents targeting specific molecular de- fects that characterize certain cancer cells in order to in- crease treatment efficacy and reduce ...breast cancer, ... See full document

16

Overcoming Innate and Acquired Therapy Resistance by Targeting DNA Repair in Human Cancer Cells

Overcoming Innate and Acquired Therapy Resistance by Targeting DNA Repair in Human Cancer Cells

... stabilizing RAD51 filament formation via its C-terminal domain, in a process separate from the functions of BRCA2 in HRR [49]. In addition, BRCA2 is active during the spindle assembly checkpoint (SAC) and promotes the ... See full document

135

Resistance relationships between platinum and parp inhibitors in ovarian cancer

Resistance relationships between platinum and parp inhibitors in ovarian cancer

... additional reversion mutation (UPN-251) and (PEO1), also suggesting that there is a selective pressure against BRCA1/2 mutations in culture. • This effect has been observed in drug resistant cell lines, as well as in ... See full document

32

Reverse the Resistance to PARP Inhibitors

Reverse the Resistance to PARP Inhibitors

... for cancer treatment. They act by inhibiting SSBs repair pathway, which is normally initiated and mediated by PARP ...that PARP inhibitors are promising in treatment of ...reducing ... See full document

11

DNA repair in cancer: emerging targets for personalized therapy

DNA repair in cancer: emerging targets for personalized therapy

... exogenous DNA damaging agents. Mammalian cells have evolved highly conserved DNA repair machinery to process DNA damage and maintain genomic ...Impaired DNA repair is a major ... See full document

16

LKB1 is a DNA damage response protein that regulates cellular sensitivity to PARP inhibitors

LKB1 is a DNA damage response protein that regulates cellular sensitivity to PARP inhibitors

... the PARP family. It binds to both SSBs and DSBs, and its role in SSBs repair via the BER pathway has been most clearly elucidated ...of PARP leads to the accumulation of SSBs, which are subsequently ... See full document

13

A decade of clinical development of PARP inhibitors in perspective.

A decade of clinical development of PARP inhibitors in perspective.

... of cancer, and often is the result of altered DNA repair capacities in tumour ...cells. DNA damage repair defects are common in different cancer types; these alterations can also ... See full document

11

Advances and perspectives of PARP inhibitors

Advances and perspectives of PARP inhibitors

... SSB repair and HR repair pathways could severely inhibit cell survival ...that PARP inhibi- tor (PARPi) could effectively kill BRCA1/2 mutated tumor cells [22, ...of PARP, but also traps ... See full document

12

PARP inhibitors: Synthetic lethality in the clinic.

PARP inhibitors: Synthetic lethality in the clinic.

... of cancer drugs that inhibit Topoisomerase II, which also “trap” a DNA repair protein on the double ...roles beyond the DDR such as transcription, apoptosis and immune function; the anti-tumor ... See full document

23

Comparative antiproliferative effects of iniparib and olaparib on a panel of triple negative and non triple negative breast cancer cell lines

Comparative antiproliferative effects of iniparib and olaparib on a panel of triple negative and non triple negative breast cancer cell lines

... reported that overexpression of miR-182 in the breast cancer cell line, MDA-MB-231 suppressed expression of BRCA1 and con- ferred sensitivity to two different PARP inhibitors. Conversely, ... See full document

9

Poly(ADP-Ribose) Polymerase-1 Inhibition: Preclinical and Clinical Development of Synthetic Lethality

Poly(ADP-Ribose) Polymerase-1 Inhibition: Preclinical and Clinical Development of Synthetic Lethality

... breast cancer BRCA mutation carriers ...ovarian cancer confirmed an overall response rate of 33% (11 pa- tients) in the 400 mg group and ...of PARP inhibitors in tumors with defective HR ...in ... See full document

9

Update on Poly ADP ribose polymerase inhibition for ovarian cancer treatment

Update on Poly ADP ribose polymerase inhibition for ovarian cancer treatment

... catalytic inhibitors blocking repair of DNA SSBs by the BER/ SSBR pathway ...to PARP inhibitors than cells deficient in BRCA1 and 2 [36, ...to PARP inhibition by a mechanism of ... See full document

18

Analogs of the novel phytohormone, strigolactone, trigger apoptosis and synergize with PARP inhibitors by inducing DNA damage and inhibiting DNA repair

Analogs of the novel phytohormone, strigolactone, trigger apoptosis and synergize with PARP inhibitors by inducing DNA damage and inhibiting DNA repair

... induce DNA damage and genomic ...of DNA damage and DSBs repair is essential for tumor cell survival [9, ...DSBs repair: an error-prone non-homologous end joining (NHEJ) that often includes ... See full document

18

Synthetic lethal targeting of oncogenic transcription factors in acute leukemia by PARP inhibitors

Synthetic lethal targeting of oncogenic transcription factors in acute leukemia by PARP inhibitors

... mutated cancer in just a decade ago, synthetic lethal approaches induced by Poly-(ADP-ribose)-polymerase (PARP) inhibitors (PARPi) have given renewed enthusiasm to developing anticancer treatments ... See full document

70

Show all 10000 documents...